CDMO focus ABL operates as a CDMO with expertise in GMP cell banks, viral vectors, bulk drug substance production, fill/finish, and process/assay development, indicating opportunities to sell biotech development and manufacturing services to vaccine and gene therapy clients advancing preclinical to Phase II.

Longevity & trust With over six decades serving the life sciences sector and a history of supporting government and commercial programs, ABL presents a stable, trusted partner profile for ongoing collaborations in regulated development work and long-term testing capabilities.

Tech enablement ABL’s technology stack includes cloud and data tools (Cloudflare, SCADA, SQL, Oracle, DocuSign, Google Tag Manager) suggesting readiness for digitized quality systems, data management, and e-signature workflows—sales angles for modernized compliance and efficiency enhancements.

Clinical reach ABL supports vaccine and therapeutic candidates through preclinical and clinical development, positioning them to engage with sponsors pursuing gene therapies, immunotherapies, viral vaccines, and oncolytic viruses seeking scalable GMP production and analytical testing.

Growth signals The company operates in a mid-sized, government-adjacent life sciences space with a substantial workforce and established manufacturing footprint, offering cross-sell opportunities for expanded testing, analytics, regulatory support, and potential partnerships with biotech firms scaling to late-stage trials.